BR9710357A - Adesina heteromultimera quimerica recomvinante isolada sequencia de acido nucleiro isolada acido nucleico isolado vetor celula hospedeira anticorpo metodo para formar um complexo adesina-ligante heteromultimera quimerica metodo para inibir a ativa-ao metodo para ativar um receptor hetermultimerico natural composicao farmaceutica artigo manufaturado e metodo para produzir anticorpo - Google Patents

Adesina heteromultimera quimerica recomvinante isolada sequencia de acido nucleiro isolada acido nucleico isolado vetor celula hospedeira anticorpo metodo para formar um complexo adesina-ligante heteromultimera quimerica metodo para inibir a ativa-ao metodo para ativar um receptor hetermultimerico natural composicao farmaceutica artigo manufaturado e metodo para produzir anticorpo

Info

Publication number
BR9710357A
BR9710357A BR9710357A BR9710357A BR9710357A BR 9710357 A BR9710357 A BR 9710357A BR 9710357 A BR9710357 A BR 9710357A BR 9710357 A BR9710357 A BR 9710357A BR 9710357 A BR9710357 A BR 9710357A
Authority
BR
Brazil
Prior art keywords
isolated
chimeric heteromultimer
heteromultimer adhesin
antibody
natural
Prior art date
Application number
BR9710357A
Other languages
English (en)
Portuguese (pt)
Inventor
Vincent Danial Fizpatrick
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BR9710357A publication Critical patent/BR9710357A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
BR9710357A 1996-07-12 1997-07-08 Adesina heteromultimera quimerica recomvinante isolada sequencia de acido nucleiro isolada acido nucleico isolado vetor celula hospedeira anticorpo metodo para formar um complexo adesina-ligante heteromultimera quimerica metodo para inibir a ativa-ao metodo para ativar um receptor hetermultimerico natural composicao farmaceutica artigo manufaturado e metodo para produzir anticorpo BR9710357A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2164096P 1996-07-12 1996-07-12
US79832697A 1997-02-10 1997-02-10
PCT/US1997/011825 WO1998002540A1 (en) 1996-07-12 1997-07-08 Chimeric heteromultimer adhesins

Publications (1)

Publication Number Publication Date
BR9710357A true BR9710357A (pt) 1999-08-17

Family

ID=26694954

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9710357A BR9710357A (pt) 1996-07-12 1997-07-08 Adesina heteromultimera quimerica recomvinante isolada sequencia de acido nucleiro isolada acido nucleico isolado vetor celula hospedeira anticorpo metodo para formar um complexo adesina-ligante heteromultimera quimerica metodo para inibir a ativa-ao metodo para ativar um receptor hetermultimerico natural composicao farmaceutica artigo manufaturado e metodo para produzir anticorpo

Country Status (13)

Country Link
US (3) US6696290B2 (enExample)
EP (2) EP0938556B1 (enExample)
JP (2) JP4274581B2 (enExample)
CN (1) CN1202247C (enExample)
AT (1) ATE486937T1 (enExample)
AU (1) AU722178B2 (enExample)
BR (1) BR9710357A (enExample)
CA (1) CA2258721C (enExample)
DE (1) DE69740038D1 (enExample)
DK (1) DK0912734T3 (enExample)
IL (1) IL127891A0 (enExample)
NZ (1) NZ333325A (enExample)
WO (1) WO1998002540A1 (enExample)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047677A2 (en) * 1998-03-17 1999-09-23 Genentech, Inc. Polypeptides homologous to vegf and bmp1
IL137176A0 (en) * 1998-01-26 2001-07-24 Genentech Inc Antibodies to 4dr and uses thereof
EP1745799B1 (en) 1998-03-04 2015-09-02 The Trustees of The University of Pennsylvania Compositions and methods of treating tumors
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US6635249B1 (en) * 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
US20030022233A1 (en) * 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
AUPQ841800A0 (en) * 2000-06-28 2000-07-20 Biomolecular Research Institute Limited Truncated egf receptor
WO2002012345A2 (en) * 2000-08-08 2002-02-14 Zymogenetics, Inc. Soluble zcytor 11 cytokine receptors
US20020119148A1 (en) * 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
WO2003012045A2 (en) * 2001-07-31 2003-02-13 Wayne State University Hybrid proteins with neuregulin heparin-binding domain for targeting to heparan sulfate proteoglycans
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
CN100424175C (zh) * 2002-03-26 2008-10-08 上海泽生科技开发有限公司 ErbB-3 用于肿瘤治疗的方法和组合物
WO2003099320A1 (en) 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
CA2506320A1 (en) * 2002-11-21 2004-06-10 Genentech, Inc. Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
EP2248899B8 (en) * 2003-03-19 2015-07-15 Biogen MA Inc. NOGO receptor binding protein
US7381794B2 (en) * 2004-03-08 2008-06-03 Zymogenetics, Inc. Dimeric fusion proteins and materials and methods for producing them
EP2474317A1 (en) 2004-06-24 2012-07-11 Biogen Idec MA Inc. Treatment of conditions involving demyelination
US7537761B2 (en) 2004-10-22 2009-05-26 Zymogenetics, Inc. Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
PL2267024T3 (pl) 2005-06-03 2012-10-31 Ares Trading Sa Wytwarzanie rekombinowanego białka wiążącego IL-18
WO2007008547A2 (en) 2005-07-08 2007-01-18 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
HUE026303T2 (hu) * 2005-07-25 2016-06-28 Emergent Product Dev Seattle B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
JP5312039B2 (ja) * 2005-12-02 2013-10-09 バイオジェン・アイデック・エムエイ・インコーポレイテッド 脱髄の関与する状態の処置
KR20090057936A (ko) * 2006-02-08 2009-06-08 타게티드 몰레큘라 다이아그노스틱스, 엘엘씨 2가 ｅｒｂｂ 리간드 결합 분자 및 그의 제조 방법 및 사용방법
CN101611150A (zh) * 2006-02-08 2009-12-23 利佳赛普特有限责任公司 二价ErbB配体结合分子及其制备和使用方法
EP1994141B1 (en) 2006-02-23 2017-11-15 ViaCyte, Inc. Compositions and methods useful for culturing differentiable cells
CN105837690A (zh) * 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
CA2655205A1 (en) * 2006-06-12 2007-12-21 Receptor Biologix Inc. Pan-cell surface receptor- specific therapeutics
WO2007147901A1 (en) * 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US7932055B2 (en) * 2006-06-22 2011-04-26 Novo Nordisk A/S Soluble heterodimeric CD94/NKG2 receptors fusion proteins
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
HRP20131113T1 (hr) 2007-02-16 2014-01-17 Merrimack Pharmaceuticals, Inc. Protutijela protiv erbb3 i njihova uporaba
US20090304590A1 (en) * 2007-05-29 2009-12-10 Wyeth Therapeutic compositions and methods
WO2008150485A2 (en) * 2007-05-29 2008-12-11 Wyeth Erbb2 binding proteins and use thereof
CA2701189C (en) * 2007-10-11 2017-05-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists
MX2010003757A (es) * 2007-10-16 2010-04-27 Symphogen As Composiciones que comprenden multimeros optimizados de her1 y her3 y sus metodos de uso.
WO2009061500A1 (en) * 2007-11-08 2009-05-14 Biogen Idec Ma Inc. Use of lingo-4 antagonists in the treatment of conditions involving demyelination
AU2009234277B2 (en) 2008-04-11 2014-12-04 Aptevo Research And Development Llc CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
JP2011527572A (ja) 2008-07-09 2011-11-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｌｉｎｇｏ抗体または断片を含む組成物
BRPI0917871A2 (pt) * 2008-08-15 2017-06-20 Merrimack Pharmaceuticals Inc agente terapêutico anti-erbb3 para uso em terapia de um tumor, métodos para predizer responsividade de um tumor de um agente terapêutco anti-erbb3, para selecionar terapia anti-erbb3 para um paciente, para predizer a resposta de células ao tratamento com um agente terapêutico, para identificar um biomarcador, e para evitar administração de uma droga para câncer anti-erbb3, e, kit para predizer a resposta das células ao tratamento com um agente terapêutico
US9198952B2 (en) 2008-09-22 2015-12-01 The Brigham And Women's Hospital, Inc. Compositions of and methods of using ligand dimers
AU2009324939B2 (en) 2008-11-25 2015-07-09 Genentech, Inc. Isoform specific anti-HER4 antibodies
AU2010281385B2 (en) * 2009-07-28 2017-06-01 Ligacept, Llc Broad spectrum ErbB ligand binding molecules and methods for preparing and using them
CA2784211C (en) * 2010-02-18 2019-12-24 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
JP2013522237A (ja) 2010-03-11 2013-06-13 メリマック ファーマシューティカルズ インコーポレーティッド トリプルネガティブおよび基底様乳癌の治療におけるｅｒｂｂ３阻害剤の使用
US9029328B2 (en) 2010-03-24 2015-05-12 The Brigham And Women's Hospital, Inc. Methods for cardioprotection and cardioregeneration with dimers of EGF family ligands
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
WO2012103114A2 (en) * 2011-01-24 2012-08-02 Jason Hill Therapeutic chimeric ligand binding proteins and methods for their use
JP2015518829A (ja) 2012-05-14 2015-07-06 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 運動ニューロンに関する状態の処置のためのｌｉｎｇｏ−２アンタゴニスト
WO2014051567A1 (en) * 2012-09-26 2014-04-03 Morehouse School Of Medicine Chimeric neuregulins and method of making and use thereof
US9745558B2 (en) 2013-02-18 2017-08-29 Vegenics Pty Limited VEGFR-3 ligand binding molecules and uses thereof
WO2015003149A2 (en) 2013-07-05 2015-01-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Soluble cd33 for treating myelodysplastic syndromes (mds)
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
AU2016205197B2 (en) 2015-01-08 2021-10-21 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
KR20180117529A (ko) 2017-04-19 2018-10-29 주식회사 프로티나 단백질-단백질 상호작용 분석에 의한 약물 반응성 예측 방법
WO2019132517A1 (ko) * 2017-12-26 2019-07-04 주식회사 프로티나 세포 내 또는 세포 간 단백질-단백질 상호작용 분석 방법 및 장치
CN110669139B (zh) * 2019-09-18 2025-12-02 沣潮医药科技（上海）有限公司 二聚体免疫粘附素、药物组合物和用途
CN111018999B (zh) * 2019-12-05 2022-07-12 沣潮医药科技（上海）有限公司 二聚体免疫融合蛋白、药物组合物和用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
PT88641B (pt) 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
EP0452364B1 (en) 1988-12-22 2002-05-22 Genentech, Inc. Method for preparing water soluble polypeptides
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
ATE144793T1 (de) 1989-06-29 1996-11-15 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
CA2037440A1 (en) 1990-03-02 1991-09-03 Gregory D. Plowman Her3: a novel egf receptor homolog
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5254536A (en) * 1992-01-10 1993-10-19 The Du Pont Merck Pharmaceutical Company Therapeutic utility of plasminogen activator inhibitor-1 to control bleeding
US5635177A (en) * 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
JP3442784B2 (ja) 1993-11-23 2003-09-02 ジェネンテク，インコーポレイテッド キナーゼ受容体活性化検定法
US5844092A (en) * 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
US5804396A (en) * 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides

Also Published As

Publication number Publication date
DK0912734T3 (da) 2011-02-07
DE69740038D1 (enExample) 2010-12-16
CA2258721C (en) 2014-09-09
NZ333325A (en) 2000-06-23
EP0938556A1 (en) 1999-09-01
AU722178B2 (en) 2000-07-27
JP2000515372A (ja) 2000-11-21
US6696290B2 (en) 2004-02-24
ATE486937T1 (de) 2010-11-15
CN1225129A (zh) 1999-08-04
JP4274581B2 (ja) 2009-06-10
JP2008115187A (ja) 2008-05-22
US20040138417A1 (en) 2004-07-15
US20030199020A1 (en) 2003-10-23
EP0938556B1 (en) 2005-03-09
AU3596297A (en) 1998-02-09
WO1998002540A1 (en) 1998-01-22
EP0912734A1 (en) 1999-05-06
US7659368B2 (en) 2010-02-09
IL127891A0 (en) 1999-10-28
CN1202247C (zh) 2005-05-18
US20070081994A1 (en) 2007-04-12
CA2258721A1 (en) 1998-01-22
EP0912734B1 (en) 2010-11-03

Similar Documents

Publication Publication Date Title
BR9710357A (pt) Adesina heteromultimera quimerica recomvinante isolada sequencia de acido nucleiro isolada acido nucleico isolado vetor celula hospedeira anticorpo metodo para formar um complexo adesina-ligante heteromultimera quimerica metodo para inibir a ativa-ao metodo para ativar um receptor hetermultimerico natural composicao farmaceutica artigo manufaturado e metodo para produzir anticorpo
IL191078A0 (en) POLYPEPTIDES WHICH BIND TO ErbB3 OR ErbB4 RECEPTOR PROTEIN TYROSINE KINASE OR BOTH, NUCLEIC ACIDS, VECTORS, HOST CELLS, COMPOSITIONS, METHOD FOR PRODUCTION AND USE OF SUCH POLYPEPTIDES
Lenferink et al. Differential endocytic routing of homo‐and hetero‐dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers
Leitinger et al. The D2 period of collagen II contains a specific binding site for the human discoidin domain receptor, DDR2
Bompard et al. Involvement of Rac in actin cytoskeleton rearrangements induced by MIM-B
Beerli et al. Intracellular expression of single chain antibodies reverts ErbB-2 transformation.
Pinkas-Kramarski et al. ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network
Doliana et al. EMI, a novel cysteine-rich domain of EMILINs and other extracellular proteins, interacts with the gC1q domains and participates in multimerization
Tzahar et al. Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network
An et al. Definition of the native and denatured type II collagen binding site for fibronectin using a recombinant collagen system
Marengere et al. Identification of residues in GTPase-activating protein Src homology 2 domains that control binding to tyrosine phosphorylated growth factor receptors and p62
KR930700662A (ko) 인간화된 단클론성 항체 및 혼성 단클론성 항체
CA2185656A1 (en) Protein tyrosine kinase agonist antibodies
Weller et al. Preparation and properties of monoclonal and polyclonal antibodies to mouse epidermal growth factor (EGF) receptors: evidence for cryptic EGF receptors in embryonal carcinoma cells
CY1109518T1 (el) Αναστολεας ενεργοποιητη αυξητικου παραγοντα ηπατοκυτταρων για χρηση σε διαμορφωση αγγειογενεσης και καρδιοαγγειωσης
BR9407512A (pt) Sequência de ácidos nucléicos vírus recombinante defectivo vetor notadamente virale composição farmaceutica e utilização de uma sequencia de ácidos nucléicos
Myers et al. Type XIX collagen purified from human umbilical cord is characterized by multiple sharp kinks delineating collagenous subdomains and by intermolecular aggregates via globular, disulfide-linked, and heparin-binding amino termini
Griggs et al. Mapping of multiple binding domains of the superantigen staphylococcal enterotoxin A for HLA.
Aumailley et al. Cell adhesion to type-VI collagen
EP0854185A3 (en) Assay receptor proteins and ligands
EP1456239A4 (en) HYBRID PROTEINS FACED WITH HEPARANSULFATE PROTEOGLYCANE WITH NEUREGULIN-HEPARIN BINDING DOMAIN
Mahadevan et al. Structural role of extracellular domain 1 of α-platelet-derived growth factor (PDGF) receptor for PDGF-AA and PDGF-BB binding
ATE279515T1 (de) Pct-65 serotonin rezeptor
BR9910568A (pt) Anticorpos agonistas de receptor de g-csf e processo de seleção para os mesmos
Cichy et al. Cytokines regulate the affinity of soluble CD44 for hyaluronan

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]